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Abstract
Scaling up access to HIV viral load testing for individuals undergoing antiretroviral therapy in 
low-resource settings is a global health priority, as emphasised by research showing the benefits of 
suppressed viral load for the individual and the whole population. Historically, large-scale 
diagnostic test implementation has been slow and incomplete because of service delivery and other 
challenges. Building on lessons from the past, in this Personal View we propose a new framework 
to accelerate viral load scale-up and ensure equitable access to this essential test. The framework 
includes the following steps: (1) ensuring adequate financial investment in scaling up this test; (2) 
achieving pricing agreements and consolidating procurement to lower prices of the test; (3) 
strengthening functional tiered laboratory networks and systems to expand access to reliable, high-
quality testing across countries; (4) strengthening national leadership, with prioritisation of 
laboratory services; and (5) demand creation and uptake of test results by clinicians, nurses, and 
patients, which will be vital in ensuring viral load tests are appropriately used to improve the 
quality of care. The use of dried blood spots to stabilise and ship samples from clinics to 
laboratories, and the use of point-of-care diagnostic tests, will also be important for ensuring 
access, especially in settings with reduced laboratory capacity. For countries that have just started 
to scale up viral load testing, lessons can be learnt from countries such as Botswana, Brazil, South 
Africa, and Thailand, which have already established viral load programmes. This framework 
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might be useful for guiding the implementation of viral load with the aim of achieving the new 
global HIV 90-90-90 goals by 2020.
Introduction
In 2014 the Joint UN Programme on HIV/AIDS (UNAIDS) announced ambitious new 
global treatment targets for 2020: 90% of people with HIV will know their status, 90% of 
people living with HIV will have access to treatment, and 90% of people on treatment will 
have suppressed viral load.1 These targets are supported by WHO recommendations from 
20162 for universal access to antiretroviral therapy (ART) and routine viral load testing to 
monitor treatment efficacy, and unequivocal evidence from the TEMPRANO ANRS 12136 
study,3 the Strategic Timing of Antiretroviral Treatment (START) study,4 and the HIV 
Prevention Trials Network 0525 study showing that ART with sustained viral suppression 
should be started early in the clinical course of HIV infection.2
The UNAIDS 90-90-90 goals present great challenges to national governments, donors, and 
technical partners, and bring focus to the need to expand access to diagnostic tests. An 
urgent priority is the introduction of routine viral load monitoring within large-scale ART 
programmes. Although CD4 monitoring has been essential in clinical decisions around 
treatment initiation and monitoring of immune reconstitution immediately following 
treatment initiation, viral load monitoring enables the detection of early signs of adherence 
problems to treatment before immunological decline.6–8 This information is crucial for 
informing adherence interventions and timely switching to second-line drug regimens, 
before drug resistance develops. Approximately 17 million people living with HIV (PLHIV) 
were on ART by 2015, reflecting an increase from 7·5 million in 2010.9 As ART coverage 
expands, investments in the global response are shifting towards ensuring the long-term 
effectiveness of ART through sustained suppression of the virus to improve survival, reduce 
HIV transmission, and prevent large-scale HIV drug resistance.10
This goal cannot be met without a substantial effort towards ensuring minimal attrition in 
each step of the care continuum. Without optimal retention in care, sustained adherence to 
medication, and effective monitoring of therapeutic response to ART, the escalating 
treatment response could result in a rapid decaying of regimen efficacy and the spread of 
drug resistance.11 Achieving long-term viral suppression within the context of early ART 
initiation will require a shift in both patient management and governmental policies to offer 
routine viral load monitoring and improved access to viral load testing capabilities in low-
income and middle-income countries (LMICs).
Access to viral load testing
In sub-Saharan Africa, where 70% of PLHIV reside, more than 6 million people who are on 
ART do not have access to viral load testing, and more than 10 million viral load tests are 
estimated to be needed in total every year.12,13 As national treatment programmes 
implement the recommendations in the 2016 WHO guidelines2—ie, immediate HIV 
treatment not just for sick patients, but for all HIV-infected individuals—the need for viral 
load testing globally will grow to as much as 30 million tests per year by 2020, with 
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increases in test demand of up to 35% annually. The provision of viral load testing 
represents one of the most urgent and large-scale priorities facing countries and the global 
health community today. Cognisant of this urgency, UNAIDS launched a global Diagnostic 
Access Initiative in 201414 to strengthen partnerships and coordination of efforts to rapidly 
expand access to diagnostic tools for ART scale-up.
Two essential considerations help define how scale-up of viral load testing should be 
approached. First, previous experiences with the introduction of new diagnostic tests in low-
resource settings suggest that implementation challenges might slow scale-up. Viral load test 
access has increased modestly between 2013 and 2015, despite the target of 90% access by 
2020.15–18 Previous large scale-up test implementation programmes provide perspective. For 
example, after nearly 10 years of CD4 test scale-up, an estimated 60% of patients in low-
resource settings had access to WHO-recommended levels of CD4 testing in 2012. Second, 
viral load tests need to be used effectively by clinicians and by patients to improve clinical 
management and adherence to ensure the goal of 90% viral suppression. A recent review of 
the large-scale implementation of molecular tuberculosis diagnostic tests in South Africa 
showed minimal impact on patient mortality, probably as a result of inadequate patient 
access to the test and poor use of test results by clinicians and patients to improve 
management.19 Linkage to care and a strong laboratory–clinic interface are essential. The 
scale-up of viral load testing provides an opportunity to apply these lessons and take more 
effective approaches to test implementation.
Addressing barriers to access to viral load
We propose the following framework (figure) for addressing barriers to access of viral load 
testing. First, substantial financial investments are needed at the outset to support the 
expansion of viral load monitoring, including laboratory infrastructure development, test 
commodities, operational costs, and downstream drug and clinical costs. In particular, 
increased switching to expensive second-line and third-line regimens could increase 
treatment budgets. Although viral load testing could lead to eventual cost savings on the 
basis of improved patient outcomes, reductions in unnecessary regimen switches, and 
reduced transmission, budget planning for increased investment in the short term will be 
necessary to ensure that these costs do not become barriers to testing scale-up. Additionally, 
increased efforts to improve access to viral load testing should be accompanied by efforts to 
improve access to effective and affordable second-line and third-line regimens. Governments 
should understand the full costs of integrating viral load testing into existing ART 
programmes to inform appropriate amounts of resource allocation towards not only testing 
supplies, but also strengthening of the supportive laboratory and clinical systems, and 
demand-generation initiatives, including patient and clinician education.
Guidance and strategies for the expansion of viral load testing programmes were released 
concurrently by the WHO, the Global Fund, the US President’s Emergency Plan for AIDS 
Relief (PEPFAR), and the African Society for Laboratory Medicine (ASLM).20 These 
strategies can help define cost-effective scale-up approaches. For example, although new 
laboratories would need to be established, existing capacity and systems for molecular HIV 
testing (eg, PCR-based testing for early infant diagnosis of HIV infection) should be 
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exploited. In 2014, instrument capacity for 2 million viral load tests was estimated to exist in 
sub-Saharan Africa, on the basis of under-used instruments in laboratories doing viral load 
and PCR-based testing for early infant diagnosis of HIV infection. Using this spare capacity 
at the launch of the scale-up of viral load testing requires rational planning and could help 
reduce early financial hurdles to test scale-up.
Second, novel approaches to financing viral load testing, such as consortium procurement 
and negotiated volume-based price reductions, instrument rental agreements, and public–
private partnership initiatives with manufacturers, could be considered. For example, major 
test procurers, including PEPFAR, The Global Fund, and the South African Government 
recently partnered under the Diagnostics Access Initiative to negotiate an access pricing 
agreement with one viral load test supplier, who reduced the test price to less than US$10 
per test, representing a nearly 40% reduction in price.21 This agreement exploited the higher 
purchasing power of these procurers to secure lower pricing for other countries and 
procurers, making the test accessible to most. Such agreements require accurate forecasts of 
test demand, realistic commodity costing, a competitive market for viral load goods and 
services, standardisation of test platforms, and predictable procurement patterns. 
Collaboration between governments and partners can help ensure that these conditions that 
facilitate sustainable low pricing are met.
Third, functional, tiered laboratory networks should be built to enable equitable test access 
from central levels to community levels of ART delivery. These networks will require both 
central, high-volume testing laboratories as well as point-of-care and mobile viral 
laboratories. Additionally, the networks will require effective specimen referral systems and 
results management and delivery systems to ensure decentralised access and rapid test 
turnaround times. These networks should include innovations in data capture and 
management, such as e-health and electronic medical records and geographical information 
systems, and the use of unmanned aerial vehicles for sample delivery from remote areas 
should be explored.22
Fourth, the scale-up of viral load testing requires the prioritisation of initiatives to ensure 
high-quality testing so that errors have a minimal impact on patients. The process of 
ensuring test quality has multiple dimensions, including product registration and regulatory 
requirements, post-market surveillance, supply chain management, proficiency testing, 
quality assurance, data management for test results (including remote wireless connectivity 
to monitor instrument and operator performance), instrument maintenance, and laboratory 
accreditation—eg, the WHO Regional Office for Africa Stepwise Laboratory Improvement 
Process Towards Accreditation (SLIPTA) programme.23 The value of quality is often 
underestimated and laboratory quality standards are not universally met. Developing an 
investment case framework for quality initiatives could help ensure consistent and 
sustainable resources are made available.
Finally, none of these efforts can occur without country ownership and leadership, as shown 
by South Africa, which as a result of its early and sustained prioritisation of viral load scale-
up had the purchasing power to help negotiate reduced prices for viral load tests that 
benefited other countries.21 Governments should give greater priority to investment in 
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laboratory services as a means of improving overall ART programme success and other 
health benefits. These HIV-related investments in laboratory services also benefit the 
management of other diseases, and help build higher capacity health systems that are better 
capable of responding to new disease threats.
Expansion of viral load testing
Simple and innovative technologies that minimise the complexities of the viral load testing 
process and extend the reach of the test to PLHIV in remote locations are also needed to 
ensure equity in access to viral load testing. These technologies include the use of dried 
blood spots instead of plasma samples,24 in line with recommendations in the 2014 WHO 
interim technical update for implementing viral load monitoring,20 and other sample 
collection and preservation devices to provide equitable access to the test to PLHIV in 
remote areas. Clear policy guidance for the use of viral load testing and the optimal 
frequency of routine monitoring for patient management also need to be made widely 
available.25 Validating the performance of point-of-care viral load tests, especially in low-
volume or remote sites, should be prioritised in parallel with the expansion of existing viral 
load testing platforms and considered for targeted viral load testing as these technologies 
become readily available. Additionally, modelling is necessary to inform deployment of viral 
load testing technology that balances new diagnostics with existing test platforms. Long-
term planning would ensure appropriate investment in technologies that enable new, 
improved platforms to be introduced in the future to further improve access.
In order to achieve the 90% viral suppression target, the global community should work 
collectively to increase equity by other means than price reduction. Demand creation, having 
the patients as stakeholders in the viral load scale-up efforts, training of health-care 
providers, and reviewing the lessons learned from past experiences in diagnostics will all 
help improve equity.
Medical professionals and patients as stakeholders
For viral load monitoring to be successful, both medical professionals and patients should 
work together to request this test when needed. Demand for the test remains low, and 
although annual viral load testing is recommended for PLHIV on ART,25 many physicians, 
nurses, and clinical officers might not order viral load tests because they are unaware of the 
advantages of virological monitoring to guide patient management or they do not know that 
the test is readily available. Alternatively, they might not have been trained on the viral load 
testing algorithm and might have difficulty interpreting viral load test results accurately or 
not know how to use the results to make appropriate decisions about when to switch 
therapies. Patients might not be aware of viral load testing, which can also contribute to low 
uptake; therefore, the opportunity to empower patients to self-manage their disease might be 
diminished. The need to educate both medical pro fessionals and patients about the reasons 
for viral load testing is clear. As these groups become familiar with the benefits of viral 
suppression and are trained on the testing process, the demand for viral load testing might 
rise while patient attrition in the clinical cascade, adherence to ART, and inappropriate 
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switches to second-line drugs might diminish, improving the management of HIV disease 
and overall health.
Lessons from the past
Many of the existing barriers to viral load adoption are not new to LMICs and can be 
mitigated through renewed focus, concerted action, and novel approaches in expanding 
access to viral load testing to millions of patients. Using lessons learned from global 
initiatives in the 1990s that helped to improve access and equity of ART in developing 
countries, a similar approach in coordinated partnerships between country governments, 
implementing partners, donors, and industry will be needed to improve access and equity to 
viral load testing.26 Much can be learned from existing national viral load testing 
programmes such as those in South Africa, Brazil, Botswana, Thailand, and Kenya on how 
to scale up viral load testing in an effective and efficient manner. Partnerships, political 
commitment, and substantial financial, operational, and technical investments were 
necessary.
Conclusion
HIV viral load monitoring is now the recommended standard of care for monitoring the 
impact of treatment and is crucial to sustain quality of care at both the patient and 
programmatic level. Expanding equitable access to viral load testing provides a clear path 
for preventing future infections and saving lives, and can be achieved by a global 
partnership. The suggestions we provide offer a framework for a concerted and harmonised 
implementation strategy that enables a rapid and cost-effective scale-up of viral load testing 
for HIV treatment monitoring. Regional bodies such as ASLM can help to galvanise 
countries to develop strategic plans for implementing viral load testing. These plans offer a 
platform for countries and partners to scale up viral load testing in a coordinated manner as 
access to ART expands and overcomes anticipated barriers at the outset.
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Figure. 
Framework for implementing sustainable viral load networks
Peter et al. Page 9
Lancet Infect Dis. Author manuscript; available in PMC 2017 December 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
